Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00750243
Recruitment Status : Completed
First Posted : September 10, 2008
Last Update Posted : October 6, 2010
Sponsor:
Information provided by:
Logical Therapeutics

Brief Summary:
The purpose of this study is to compare naproxen plasma levels and gastroduodenal mucosal injury after administration of LT-NS001 as compared to Naprosyn in subjects age 45-70.

Condition or disease Intervention/treatment Phase
Healthy Drug: LT-NS001 Drug: Naprosyn® Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation
Study Start Date : September 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Experimental: A Drug: LT-NS001
1200 mg b.i.d. p.o. for 7.5 days

Active Comparator: B Drug: Naprosyn®
500 mg b.i.d. p.o. for 7.5 days




Primary Outcome Measures :
  1. Assessment of GI mucosal injury by endoscopy [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. Comparison of naproxen PK at steady state [ Time Frame: 7.5 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI 18-30 kg/m2
  • No NSAID's for 14 days prior to baseline endoscopy

Exclusion Criteria:

  • Pregnant/Nursing women
  • History of documented gastroduodenal ulcer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00750243


Locations
Layout table for location information
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Logical Therapeutics
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: K. Lea Sewell, M.D., Logical Therapeutics
ClinicalTrials.gov Identifier: NCT00750243    
Other Study ID Numbers: LT-NS001-002
First Posted: September 10, 2008    Key Record Dates
Last Update Posted: October 6, 2010
Last Verified: October 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Naproxen
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action